Applied DNA Sciences, Inc. Expands Executive Sales Team

STONY BROOK, NY--(Marketwire - October 13, 2009) -

Highlighted Links

APDN SigNature DNA Markers

APDN Cash-in-Transit

Applied DNA Sciences, Inc. (OTCBB: APDN), a provider of DNA-based security solutions, announced that it has expanded its sales force to include a number of veteran industry and government consultants who will be responsible for driving sales and strategic business initiatives throughout the U.S. and abroad. The new additions include Joseph L. Magno, an expert in government relations, Warren M. Pearlson, a veteran in pharmaceuticals, and others with expertise in cash-in-transit, wine, textiles and B2B technology commercialization.

Mr. Magno brings extensive government experience and is working with APDN to initiate strategies to effectively penetrate State and Federal Government organizations. He successfully founded and led a number of technologically-driven companies, his last being acquired and sold to General Electric in 1996. Earlier in his career, Mr. Magno held positions in sales and management in a number of large multi-national technology companies. While serving in government, he advised both the New York State Governor and Legislative Leadership on economic development, research and education. Mr. Magno has served on a number of boards including NYSTAR, University at Albany Bioscience Development Center, NYS Software Network, NYS Institute for Entrepreneurship and currently serves on the Watervliet Arsenal Partnership Board and the Albany Science and Technology Law Center Board of Advisors.

"I am delighted to spearhead a number of initiatives to help protect products within government supply and logistic chains and ultimately ensure public safety. It's reassuring to know that DNA technology is available to provide the necessary forensic checks and balances not sufficiently addressed by other security measures," commented Mr. Magno.

Mr. Pearlson is a 25-year veteran in the pharmaceutical industry including positions of increasing responsibility at Astra Pharmaceuticals, Warner Lambert/Parke-Davis and most recently with Pfizer. His extensive industry network of contacts and strategic management skills will establish the client base most positively impacted by DNA technology.

"Companies have the ability and the obligation to put systems in place to protect the public. Not only do counterfeit drugs defraud consumers, they can cause great harm and even fatalities. DNA provides a forensic level of confidence which is why it is so appealing to providers and consumers," stated Mr. Pearlson.

Over the last year, APDN has evolved an integrated, global matrix of sales consultants and regional representatives compensated largely by sales commissions. In addition to four newly appointed sales consultants, the company recently began collaborating with a British Wine Master to help us sell our authentication technologies in Bordeaux and throughout Europe.

"We have demonstrated our ability to execute and provide first-category services across multiple sectors," said Dr. James Hayward, CEO of APDN. "With the expansion of our sales force, we expect our sales cycle to shorten and our penetration within sectors to increase."

About APDN

APDN sells patented DNA security solutions to protect products, brands and intellectual property from counterfeiting and diversion. SigNature DNA is a botanical mark used to authenticate products in a unique manner that essentially cannot be copied. APDN also provides BioMaterial GenoTyping™ by detecting genomic DNA in natural materials to authenticate finished products. Both technologies protect brands and products in a wide range of industries and provide a forensic chain of evidence that can be used to prosecute perpetrators. To learn more, go to www.adnas.com where APDN routinely posts all press releases.

The statements made by APDN may be forward-looking in nature and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe APDN's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN's SEC reports and filings, including our Annual Report on Form 10-K, filed on December 16, 2008 and our subsequent quarterly reports on Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati: DNA forensic government state federal B2B pharmaceuticals drugs counterfeit Pfizer wine